Novavax initiated phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
Resilience to manufacture mRNA for Moderna’s COVID-19 vaccine
On Sept. 8, 2021, National Resilience announced an agreement to manufacture mRNA for the Moderna COVID-19 vaccine. Under…
Takeda announced manufacture and provision of 150 million doses of Novavax COVID-19 vaccine candidate to the government of Japan
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…
Moderna announced submission of data to EMA for its COVID-19 vaccine booster
On Sept. 3, 2021, Moderna announced that it had submitted for a conditional marketing approval (CMA) with the…
Moderna announced submission of initial data to U.S. FDA for Its COVID-19 vaccine booster
On Sept. 1, 2021, Moderna announced it had initiated its submission to the U.S. Food and Drug Administration…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Non-Profit Research | Therapeutics
Monoclonal antibody treatment combo reduced hospitalization among high-risk patients with COVID-19
On Aug. 30, 2021, the Mayo Clinic reported that in an observational study the combination of casirivimab and…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Study confirmed virus variants reduce protection against COVID-19
On Aug. 26, 2021, Oregon Health & Science University (OHSU) announced a laboratory study from found that blood…
Anixa Biosciences’ Covid-19 compounds expected to be effective against the Delta variant
On Aug. 25, 2021, Anixa Biosciences announced that a genomic variant analysis indicateed that its potential compounds may…
Moderna completed submission of BLA to the Food and Drug Administration for its COVID-19 vaccine
On Aug. 25, 2021, Moderna announced it had completed the rolling submission process for its Biologics License Application…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…
Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024
On Aug. 16, 2021, Moderna announced a revised supply agreement with the Government of Canada for up to…
Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals
On Aug. 13, 2021, Moderna announced that the Food and Drug Administration (FDA) had approved an update to…
The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
On Aug. 12, 2021, the U.S. Department of Veterans Affairs (VA) announced that it expanded his previous COVID-19…
Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern
On Aug. 12, 2021, Moderna announced the publication of new data on the durability of the Moderna COVID-19…
Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock
On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…
NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients
On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…
Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada
On Aug. 10, 2021, Moderna announced a Memorandum of Understanding (MoU) with the government of Canada to build…
Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine
On Aug. 9, 2021, Moderna announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the…
INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…
Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccine
On Aug. 3, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine
On Jul. 29, 2021, Vaxart announced that it has shown for the first time in clinical trials that…
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…
Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines
On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council…
CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU
On Jul. 23, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster
On Jul. 22, 2021, Moderna announced a new supply agreement with Taiwan for 20 million doses of Moderna’s…
Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…
Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine
On Jul. 12, 2021, Moderna announced a supply agreement with the government of Argentina for 20 million doses…